AbCellera Biologics Inc. Common Shares
Here’s whether AbCellera Biologics Inc. Common Shares (ABCL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+8.97% over 10 days); strong 1-year return of +152.9%; 3-month momentum positive (+178.2%); rising volume confirms the move (1.68x 30d avg). Concerns: RSI 97 — overbought, elevated pullback risk. Currently 1.0% off its 52-week high. Score: +6/7.
ABCL is in a confirmed uptrend, trading above both its 50-day ($6.62) and 200-day ($4.61) moving averages. With an RSI of 97.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +152.9% compares to +20.4% for SPY (beat the market by 132.5%).